HBV Treatment
Long-term Adefovir (Hepsera) plus Emtricitabine (Emtriva) vs Adefovir Monotherapy for Chronic Hepatitis B
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 18 March 2008 14:01
- Written by HIVandHepatitis.com
Antiviral therapy with nucleoside/nucleotide analog agents is effective against chronic hepatitis B virus (HBV) infection, but long-term efficacy is limited by the emergence of drug resistant virus. As reported in the May 2008 Journal of Hepatology, researchers from the University of Hong Kong conducted a trial to determine the efficacy of adefovir dipivoxil (Hepsera) plus emtricitabine (Emtriva) combination therapy in patients with chronic hepatitis B. Adefovir is currently approved for this indication; emtricitabine is approved for the treatment of HIV, but is still under investigation for HBV.
Adefovir (Hepsera) for Treatment of Patients with Chronic Hepatitis B Resistant to Lamivudine (Epivir)
- Details
- Category: HBV Treatment
- Published on Tuesday, 04 March 2008 13:01
- Written by HIVandHepatitis.com
In a prospective cohort study, 29 participants with lamivudine-resistant HBV were treated with adefovir (Hepsera) alone, while 23 continued lamivudine and added adefovir.
Web Design and Development by